⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Global Precision Medicine Biotechnology Solutions Market - Strategic Insights and Forecasts, 2026-2031 | AI and Genomics Fuel 11.3% CAGR, Creating a $49.6 Billion Opportunity
globenewswire.com
PFE
NVS
AZN
TMO
BMY
AMGN
ILMN
QGEN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
accessnewswire.com
NVS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
accessnewswire.com
NVS
American Kidney Fund’s UCKD Summit Helps Drive Early Recognition for Rare and Genetic Kidney Diseases
globenewswire.com
NVS
TVTX
VRTX
ALNY
NTRA
SNY
Form 8-K
sec.gov
QNCX
GSK
AZN
ZYME
TNYA
NTAP
EXEL
NVS
KLRS
NKTX
CLYM
INSM
France Radiopharmaceuticals and Theranostics Market Size, Trends, and Forecast to 2035 | Market to Reach $1.03 Billion as Radioligand Therapy and Isotope Capacity Expands
globenewswire.com
NVS
CAH
Europe CAR-T Therapies Market for Autoimmune Disorders: Trends, Growth, and Forecast to 2035 | 47.4% CAGR Signals a USD 1.25 Billion Opportunity as Clinical Pipelines Advance
globenewswire.com
AUTL
KYMR
NVS
SANA
JNJ
Targeted Cancer Therapy Market Size and Forecast by Therapy Type, Disease Indication, End-User, and Region, 2026-2035 | Precision Oncology Drives 6.8% CAGR Toward $175.48 Billion
globenewswire.com
AZN
NVS
Europe Alpha-Emitting Radioligand Therapy Market Trends and Forecast to 2035 | 26% CAGR Drives Market Toward USD 0.40 Billion as Isotope Capacity and Oncology Pipelines Expand
globenewswire.com
NVS
LLY
BMY
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity
globenewswire.com
AZN
NVS
ROG